Literature DB >> 33291235

Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial Infarction.

Elias Haj-Yehia1, Robert Werner Mertens1, Florian Kahles1, Marcia Viviane Rückbeil2, Matthias Rau1, Julia Moellmann1, Moritz Biener3, Mohammad Almalla1, Jörg Schroeder1, Evangelos Giannitsis3, Hugo Albert Katus3, Nikolaus Marx1, Michael Lehrke1.   

Abstract

AIMS: Recent studies have found circulating concentrations of the gastrointestinal hormone GLP-1 to be an excellent predictor of cardiovascular risk in patients with myocardial infarction. This illustrates a yet not appreciated crosstalk between the gastrointestinal and cardiovascular systems, which requires further investigation. The gut-derived hormone Peptide YY (PYY) is secreted from the same intestinal L-cells as GLP-1. Relevance of PYY in the context of cardiovascular disease has not been explored. In this study, we aimed to investigate PYY serum concentrations in patients with acute myocardial infarction and to evaluate their association with cardiovascular events.
MATERIAL AND METHODS: PYY levels were assessed in 834 patients presenting with acute myocardial infarction (553 Non-ST-Elevation Myocardial Infarction (NSTEMI) and 281 ST-Elevation Myocardial Infarction (STEMI)) at the time of hospital admission. The composite outcomes of first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke (3-P-MACE), and all-cause mortality were assessed with a median follow-up of 338 days.
RESULTS: PYY levels were significantly associated with age and cardiovascular risk factors, including hypertension, diabetes, and kidney function in addition to biomarkers of heart failure (NT-pro BNP) and inflammation (hs-CRP). Further, PYY was significantly associated with 3-P-MACE (HR: 1.7; 95% CI: 1-2.97; p = 0.0495) and all-cause mortality (HR: 2.69; 95% CI: 1.61-4.47; p = 0.0001) by univariable Cox regression analyses, which was however lost after adjusting for multiple confounders.
CONCLUSIONS: PYY levels are associated with parameters of cardiovascular risk as well as cardiovascular events and mortality in patients presenting with acute myocardial infarction. However, this significant association is lost after adjustment for further confounders.

Entities:  

Keywords:  PYY; cardiovascular risk; gut hormone; mortality; myocardial infarction

Year:  2020        PMID: 33291235      PMCID: PMC7762108          DOI: 10.3390/jcm9123952

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  40 in total

1.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Authors:  Hertzel C Gerstein; Helen M Colhoun; Gilles R Dagenais; Rafael Diaz; Mark Lakshmanan; Prem Pais; Jeffrey Probstfield; Jeffrey S Riesmeyer; Matthew C Riddle; Lars Rydén; Denis Xavier; Charles Messan Atisso; Leanne Dyal; Stephanie Hall; Purnima Rao-Melacini; Gloria Wong; Alvaro Avezum; Jan Basile; Namsik Chung; Ignacio Conget; William C Cushman; Edward Franek; Nicolae Hancu; Markolf Hanefeld; Shaun Holt; Petr Jansky; Matyas Keltai; Fernando Lanas; Lawrence A Leiter; Patricio Lopez-Jaramillo; Ernesto German Cardona Munoz; Valdis Pirags; Nana Pogosova; Peter J Raubenheimer; Jonathan E Shaw; Wayne H-H Sheu; Theodora Temelkova-Kurktschiev
Journal:  Lancet       Date:  2019-06-09       Impact factor: 79.321

2.  Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation.

Authors:  María del Puy Heredia; Carmen Delgado; Laetitia Pereira; Romain Perrier; Sylvain Richard; Guy Vassort; Jean-Pierre Bénitah; Ana María Gómez
Journal:  J Mol Cell Cardiol       Date:  2004-12-09       Impact factor: 5.000

3.  Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility.

Authors:  J M Lundberg; K Tatemoto; L Terenius; P M Hellström; V Mutt; T Hökfelt; B Hamberger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

4.  Mechanism of action of peptide YY to inhibit gastric motility.

Authors:  J W Wiley; Y X Lu; O Y Chung
Journal:  Gastroenterology       Date:  1991-04       Impact factor: 22.682

5.  Renal and cardiac neuropeptide Y and NPY receptors in a rat model of congestive heart failure.

Authors:  Ean Y Callanan; Edward W Lee; Jason U Tilan; Joseph Winaver; Aviad Haramati; Susan E Mulroney; Zofia Zukowska
Journal:  Am J Physiol Renal Physiol       Date:  2007-09-05

6.  Short-term regulation of peptide YY secretion by a mixed meal or peritoneal glucose-based dialysate in patients with chronic renal failure.

Authors:  Miguel Pérez-Fontán; Fernando Cordido; Ana Rodríguez-Carmona; Manuel Penín; Helena Díaz-Cambre; Andrés López-Muñiz; Susana Sangiao-Alvarellos; Jesús García-Buela
Journal:  Nephrol Dial Transplant       Date:  2008-05-23       Impact factor: 5.992

7.  Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV.

Authors:  R Mentlein; P Dahms; D Grandt; R Krüger
Journal:  Regul Pept       Date:  1993-12-10

8.  PYY plays a key role in the resolution of diabetes following bariatric surgery in humans.

Authors:  Claudia Guida; Sam D Stephen; Michael Watson; Niall Dempster; Pierre Larraufie; Thomas Marjot; Tamsin Cargill; Lisa Rickers; Michael Pavlides; Jeremy Tomlinson; Jeremy F L Cobbold; Chun-Mei Zhao; Duan Chen; Fiona Gribble; Frank Reimann; Richard Gillies; Bruno Sgromo; Patrik Rorsman; John D Ryan; Reshma D Ramracheya
Journal:  EBioMedicine       Date:  2019-01-11       Impact factor: 8.143

9.  Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction.

Authors:  Neil Herring; Nidi Tapoulal; Manish Kalla; Xi Ye; Lyudmyla Borysova; Regent Lee; Erica Dall'Armellina; Christopher Stanley; Raimondo Ascione; Chieh-Ju Lu; Adrian P Banning; Robin P Choudhury; Stefan Neubauer; Kim Dora; Rajesh K Kharbanda; Keith M Channon
Journal:  Eur Heart J       Date:  2019-06-21       Impact factor: 29.983

10.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

Authors:  Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

View more
  2 in total

1.  High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.

Authors:  Songwei Li; Jian Huang; Fan Yang; Haiping Zeng; Yuyun Tong; Kejia Li
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

2.  Effect of Combined Antiretroviral Therapy on the Levels of Selected Parameters Reflecting Metabolic and Inflammatory Disturbances in HIV-Infected Patients.

Authors:  Karolina Jurkowska; Beata Szymańska; Brygida Knysz; Agnieszka Piwowar
Journal:  J Clin Med       Date:  2022-03-19       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.